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, is one such de-bulking agent that has greatly contributed to improved outcomes observed in MM 4 Despite this advance, however, relapse following bortezomib therapy remains inevitable due to the emergence of bortezomib-resistant plasma cell sub-clones 5 For example; recent 'whole genome' sequencing studies of MM patients confirmed a high level of genetic heterogeneity; occurring both between separate patients, and within patient samples before and after therapy 6 , indicating the presence of a variety of genetically distinct plasma cell 'sub-clones' 7, 8 Different sub-clones further indicate the presence of numerous minor tumour initiating cell populations with complex and divergent evolutionary histories 9 . The potential quiescence of these MM sub-clones, coupled with their diversity, can contribute to enhanced tumorigenicity and an intrinsic resistance to therapy 10 . Therefore; the eradication of the majority bortezomib-sensitive sub-clones may ultimately promote the growth of pre-existing minority bortezomib-resistant sub-clones, limiting the observation that approximately half of initially bortezomib-sensitive MM patients are no longer able to respond to bortezomib once relapsed. 11 This sub-clonal bortezomib-resistance has been attributed to a range of mechanisms; including enhanced growth factor expression 12 , mutated proteasome subunits 13 , deregulated plasma cell maturation markers 14 , and nuclear factor-kappa B (NF-κB) pathway 'addiction' 15 [for a more in-depth exploration of this topic see Murray et al. 2014 16 ].
Furthermore, pro-survival NF-κB signalling pathway members were also found to have a broader than anticipated profile in MM whole genome sequencing data. 6 These findings are consistent with our previous studies into the role of NF-κB signalling in haematological malignancies [17] [18] [19] , suggesting that a greater understanding of the NF-κB signaling network in bortezomib-resistant MM may be central to achieving therapeutic advances in this disease.
In its primary mode of action bortezomib successfully inhibits 'inducible' NF-κB expression in MM cells, such as the expression stimulated by MM-bone marrow stromal cell (BMSC) interaction 20 , via its function as an inhibitor of the 20s proteasome β5 subunit. 21 Conversely, however, bortezomib also enhances 'constitutive' levels of NF-κB through activation of IKKβ, ultimately leading to NF-κB nuclear translocation and the transcription of multiple NF-κB-induced genes, including Bruton's tyrosine kinase (BTK). 22 BTK, a non-receptor tyrosine kinase, is now known to be of key importance to a number of haematological malignancies, including MM
23
, chronic lymphocytic leukemia (CLL) 24 and acute myeloid leukemia (AML). 25 The potential feedback mechanism between NF-κB and BTK signalling, whereby BTK also lies upstream of several NF-κB inducible signalling pathways 26, 27 , provides a rationale for investigation of combined NF-κB and BTK inhibition in MM.
A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t
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Previously we and others have shown ex vivo efficacy of BTK inhibition in MM. 17, 23 Specifically, we have shown that the irreversible BTK inhibitor ibrutinib can enhance the action of bortezomib via repression of the NF-κB survival pathway in primary tissue, e.g., bone marrow-derived MM cells from treatment-naïve patients. 17 Despite these findings, however, early phase II clinical trial data for ibrutinib monotherapy in MM have so far proved disappointing 28 , whilst the study of ibrutinib efficacy in patients with relapsed of refractory MM is currently recruiting (ClinicalTrials.gov
Identifier:NCT01478581).
Taken together these data highlight the need to develop novel therapeutic strategies that can overcome bortezomib-resistance 16 , whilst still de-bulking the tumour and protecting the patient from related organ and tissue impairment.
MM clonal development and selection is impacted by the timing, order, and combinations of therapies received; however, all patients treated with bortezomib therapy are destined to relapse and become bortezomib-resistant. Here, we utilise in vitro modelling to demonstrate BTK pro-survival pathway activity in bortezomibresistant MM. These data provide justification for further assessment of greater patient numbers in the clinic, which will establish whether ibrutinib therapy can be used to overcome bortezomib-resistance in MM in practice.
Results

Generation and characterisation of bortezomib-resistant MM cells
To determine the importance of the BTK pro-survival pathway in bortezomibresistance we first generated bortezomib-resistant cells in vitro. We cultured MM- We also analysed primary human treatment-naïve MM patient samples (primary naïve; n=5) and primary human MM samples from patients that had initially responded to bortezomib but subsequently relapsed (primary relapsed; n=6). All 
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Basal BTK activity is enhanced in bortezomib-resistant MM cell lines and is resistant to inhibition with bortezomib
We have previously shown that the BTK pathway is active in MM. 17 Furthermore, others have shown that bortezomib can reduce the expression of BTK mRNA and protein via an NF-κB p65-dependent mechanism. 
Bortezomib-resistance is driven by enhanced NF-κB p65 activity and can be reversed by BTK inhibition
We have previously shown that BTK inhibition reduces NF-κB p65 activity in bortezomib-naïve MM cells and primary naïve patient samples. 17 To determine the role of NF-κB p65 in the regulation of BTK activity in bortezomib-resistant MM cells we initially examined basal levels of sub-cellular NF-κB p65 protein distribution in bortezomib-naïve and bortezomib-resistant U266 MM cells by immunocytochemistry.
Utilising an antibody against the NF-κB p65 subunit we observed higher levels p65 in the nucleus of bortezomib-resistant cells compared to bortezomib-naïve cells [n≥20], Importantly, bortezomib-resistant cells showed no significant reduction in NF-κB p65 nuclear localisation in response to bortezomib treatment alone compared to bortezomib-naïve cells, potentially suggesting a level of constitutive NF-κB p65 activity in these cells.
To confirm the functional relevance of enhanced basal nuclear NF-κB p65 localisation in bortezomib-resistant MM cells, and to confirm that any response to bortezomib observed was specifically due to its ability to repress inducible NF-κB p65 activity, we generated artificial and exogenous miRNA sequences specifically targeting NF-κB p65 (miRp65) and utilised lenti-viral infection to achieve semi-stable p65 mRNA knockdown in bortezomib-naïve and bortezomib-resistant U266 MM cells 
Discussion
The proteasome inhibitor bortezomib is licensed to treat newly diagnosed and relapsed MM in the clinic. Single agent bortezomib has a response rate of approximately 30% but, when used in combination with chemotherapy and/or corticosteroids, response rates range from approximately 60% to over 90% depending on the regimen. 16 Despite this relative success, however, clinical relapse following bortezomib therapy presently remains inevitable and resistance to further bortezomib treatment is common 30, 31 , not only as a consequence of, but also further driving the selection and emergence of drug-resistant clones. We and others have previously demonstrated activity of the BTK survival pathway in treatment-naïve MM cells. 17, 33 Furthermore, bortezomib has been reported to inhibit total BTK expression in a treatment-naive B lymphocyte cell line. 22 Here, utilising in vitro models of post-bortezomib relapsed MM, we describe a role for BTK activity in bortezomib-resistance, demonstrating higher basal levels of active pBTK protein in bortezomib-resistant MM cell lines and a failure of these cells to respond to The oral BTK inhibitor ibrutinib, currently licenced for use in CLL and MCL 34, 35 , has
shown promising clinical activity and a favourable side-effect profile in a range of B cell malignancies. [36] [37] [38] [39] Ibrutinib has also been found to reduce BTK expression in MM 22 and enhance the cytotoxicity of bortezomib in bortezomib-naïve primary malignant plasma cells and MM cell lines. 17 By inhibiting BTK with ibrutinib 'pulse' treatment we were also able to restore a measurable cytotoxic response to bortezomib in bortezomib-resistant MM cell lines and primary relapsed MM cells.
Importantly, although ibrutinib is known to target other kinases, we were able to reproduce these results with highly specific artificial BTK-targeting microRNA, miRBTK, introduced by lenti-virus. This suggests that it is BTK inhibition which is restoring bortezomib activity in bortezomib-resistant MM cells and not an off target effect of ibrutinib.
Multiple mechanisms of action of bortezomib have been described 20, 16 , including the inhibition of BTK expression driven via repression of inducible NF-κB transcription factor translocation to the nucleus. 17, 22, 40 We found enhanced nuclear localisation of NF-kB p65 in the bortezomib-resistant cells. This is in-keeping with previous reports that bortezomib-resistance in MM is conveyed through the NF-κB signalling network.
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For example; constitutive expression of NF-κB is frequently seen in bortezomib refractory primary patient samples. 41 Furthermore, the acquisition of bortezomibresistance can follow up-regulation of heat shock protein (HSP)90 and HSP27, which, in their action as ubiquitin chaperones, facilitate the activation of NF-κB in MM. 42, 43 Active pBTK is also known to be essential for NF-κB activation and B cell survival. 44 Thus, there exists a positive auto-regulatory feedback loop that stimulates transcription of BTK via two functionally competent NF-κB p65 sites in the BTK promoter. 22 Here we show that bortezomib-resistance in MM is associated with higher basal nuclear NF-κB p65 in bortezomib-resistant MM cells, which, in turn, is associated with a greater reliance on pBTK for survival. These observations suggest that BTK inhibition by ibrutinib may be useful in the clinical treatment of bortezomibresistant MM. 07/H0310/146) and were isolated from the bone marrow aspirates of MM patients, as described previously. 17 Primary MM cells from bortezomib-relapsed patients were not exposed to further bortezomib treatment until experimentation.
Ibrutinib 'pulse' treatment
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To mimic in vivo pharmacokinetics of rapid adsorption and elimination of the irreversible BTK inhibitor ibrutinib 45 , we employed a method of 'pulse' exposure to physiologically relevant levels of ibrutinib in vitro, as described previously. 46 Briefly, cells were exposed to 500 nM ibrutinib for 1 h before washing, followed by any additional drug treatment or assay in fresh media. Image analyses and quantification of pBTK vs. BTK, and nuc. vs. cyt. p65 staining intensity was performed using ImageJ 1.46 software (National Institute of Health) and plugins, as described previously. 25 Briefly, a threshold of staining intensity was applied and the area above the threshold (pixles 
Luminescent cell viability assay and chymotrypsin-like proteasome activity assay
Western Immunoblotting
Protein fractions of equal total protein concentration were extracted from U266 MM cells using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. SDS/PAGE and western immunoblot analyses were performed as described previously 47 . ECL detection using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) and subsequent quantification were performed with the ChemiDoc-It2 Imaging System (UVP).
RNA extraction and quantitative real time-PCR
Total RNA was extracted from 1 x 10 6 U266 MM cells using Total RNA Lysis Solution (Applied Biosystems-Life Technologies) according to the manufacturer's instructions.
Reverse transcription of total RNA was performed using the GeneAmp® Gold RNA and an EmGFP-pre-miRNA encoding fragment, were constructed and produced as described previously.25 Briefly, artificial miRNA targets were identified and designed to interact with the relevant exon using Block-iT RNAi designer software (Invitrogen).
This ensures high specificity of miR-p65 and miR-BTK, with no 3'UTR interaction, unlike endogenous miRNAs. 
Chemi-luminescent luciferase reporter assay
Firefly and Renilla promoter-luciferase reporter activity was analysed and quantified sequentially in a single sample with the Dual-Luciferase ® Reporter Assay System 
